EP3997128A4 - Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies - Google Patents

Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies Download PDF

Info

Publication number
EP3997128A4
EP3997128A4 EP20836912.4A EP20836912A EP3997128A4 EP 3997128 A4 EP3997128 A4 EP 3997128A4 EP 20836912 A EP20836912 A EP 20836912A EP 3997128 A4 EP3997128 A4 EP 3997128A4
Authority
EP
European Patent Office
Prior art keywords
hsc
patient
hematopoietic
stem cells
specific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20836912.4A
Other languages
German (de)
French (fr)
Other versions
EP3997128A1 (en
Inventor
Vladislav Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemogenyx Pharmaceuticals LLC
Original Assignee
Hemogenyx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/506,764 external-priority patent/US11104738B2/en
Application filed by Hemogenyx Pharmaceuticals LLC filed Critical Hemogenyx Pharmaceuticals LLC
Publication of EP3997128A1 publication Critical patent/EP3997128A1/en
Publication of EP3997128A4 publication Critical patent/EP3997128A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP20836912.4A 2019-07-09 2020-07-08 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies Withdrawn EP3997128A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,764 US11104738B2 (en) 2016-04-04 2019-07-09 Monoclonal antibodies to human FLT3/FLK2 receptor protein
PCT/US2020/041095 WO2021007266A1 (en) 2019-07-09 2020-07-08 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Publications (2)

Publication Number Publication Date
EP3997128A1 EP3997128A1 (en) 2022-05-18
EP3997128A4 true EP3997128A4 (en) 2023-10-18

Family

ID=74115143

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20836912.4A Withdrawn EP3997128A4 (en) 2019-07-09 2020-07-08 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Country Status (5)

Country Link
EP (1) EP3997128A4 (en)
JP (1) JP2022540602A (en)
CN (1) CN114829399A (en)
CA (1) CA3146912A1 (en)
WO (1) WO2021007266A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009181A (en) * 2015-01-26 2017-11-22 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY.
JP2019513836A (en) * 2016-04-04 2019-05-30 ヘモジェニックス リミテッド ライアビリティ カンパニー Method of Depleting Hematopoietic Stem / Hematopoietic Progenitor Cells (HSC / HP) in a Patient Using a Bispecific Antibody
ES2905377T3 (en) * 2017-04-18 2022-04-08 Autolus Ltd Cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells

Also Published As

Publication number Publication date
WO2021007266A1 (en) 2021-01-14
CA3146912A1 (en) 2021-01-14
EP3997128A1 (en) 2022-05-18
JP2022540602A (en) 2022-09-16
CN114829399A (en) 2022-07-29

Similar Documents

Publication Publication Date Title
EP3439699A4 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP3924375A4 (en) Universal donor stem cells and related methods
EP3933032A4 (en) Three-dimensional culture method for large-scale preparation of stem cells
EP3914271A4 (en) Compositions and methods for generating hematopoietic stem cells (hscs)
EP3802790A4 (en) Methods for generating hematopoietic stem cells
EP4024533A4 (en) Secondary battery, apparatus comprising secondary battery, preparation method for secondary battery, and adhesive composition
EP3969560A4 (en) Microfluidic device and method of use for cell culture
EP3980067A4 (en) Antibody-interleukin fusion protein and methods of use
EP3927352A4 (en) Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
IL294152A (en) Method for culturing hematopoietic stem cells
EP3959996A4 (en) Emulsion composition using seed storage protein and method for producing same
AU2022241885A1 (en) Methods for obtaining induced pluripotent stem cells
EP3997128A4 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP3985103A4 (en) Cells capable of differentiating into placenta-constituting cells, and method for producing same
EP3933022A4 (en) Method for manufacturing culture vessel, and culture vessel
EP4051782A4 (en) Medium and methods for culturing organoids
EP3947660A4 (en) Enpp1 polypeptides and methods of using same
EP3979360A4 (en) All-solid-state battery and method for producing same
EP3778865A4 (en) Novel cell and method for producing protein of interest using same
EP4022795A4 (en) Apparatuses and methods for sequential receive combining
EP3922115A4 (en) Disposable dual-channel cigarette and preparation method therefor
EP3950932A4 (en) Method for producing pluripotent stem cells capable of differentiating into specific cells, and application thereof
EP3874027A4 (en) Methods for hematopoietic stem and progenitor cell transplant therapy
EP4072570A4 (en) Methods for generating hematopoietic stem cells
EP4079844A4 (en) Method of microglia differentiation capable of securing large quantity of microglia by using 3d organoids from human pluripotent stem cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230606BHEP

Ipc: A61P 37/06 20060101ALI20230606BHEP

Ipc: A61K 45/06 20060101ALI20230606BHEP

Ipc: A61K 39/395 20060101ALI20230606BHEP

Ipc: C07K 16/28 20060101AFI20230606BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230908BHEP

Ipc: A61P 37/06 20060101ALI20230908BHEP

Ipc: A61K 45/06 20060101ALI20230908BHEP

Ipc: A61K 39/395 20060101ALI20230908BHEP

Ipc: C07K 16/28 20060101AFI20230908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240219